Valuation: Gilead Sciences, Inc.

Market Cap 161B 141B 131B 120B 226B 15,461B 230B 1,557B 608B 7,601B 603B 590B 26,281B P/E 2026 *
-46.6x
P/E 2027 * 16.4x
Enterprise Value 170B 149B 139B 127B 239B 16,372B 243B 1,649B 644B 8,049B 638B 624B 27,830B EV / Sales 2026 *
5.59x
EV / Sales 2027 * 4.97x
Free-Float
99.88%
Yield 2026 *
2.55%
Yield 2027 * 2.64%
1 day-0.93%
1 week-3.70%
Current month+2.35%
1 month+3.32%
3 months-0.84%
6 months-4.87%
Current year+5.35%
1 week 127.61
Extreme 127.61
135.5
1 month 124.19
Extreme 124.19
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%-3.70%+14.23%+66.51% 162B
+0.86%+1.43%+48.50%+160.39% 1,057B
+1.59%+4.09%+55.34%+53.96% 624B
+0.95%+1.91%+35.91%+81.14% 454B
+1.60%+6.25%+33.95%+29.84% 341B
-0.60%+1.52%+35.68%+39.76% 297B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 215B
+1.22%+2.66%+21.87%+59.73% 201B
-0.16%-2.04%-3.20%-34.58% 143B
Average +0.31%+0.93%+23.02%+43.26% 375.65B
Weighted average by Cap. +0.51%+1.77%+34.26%+73.36%

Financials

2026 *2027 *
Net sales 30.42B 26.72B 24.85B 22.8B 42.84B 2,930B 43.5B 295B 115B 1,440B 114B 112B 4,980B 32.28B 28.35B 26.37B 24.2B 45.46B 3,109B 46.16B 313B 122B 1,528B 121B 119B 5,285B
Net income -3.39B -2.98B -2.77B -2.54B -4.78B -327B -4.85B -32.89B -12.85B -161B -12.73B -12.46B -555B 9.76B 8.57B 7.97B 7.32B 13.75B 940B 13.96B 94.68B 36.99B 462B 36.65B 35.86B 1,598B
Net Debt 9.46B 8.31B 7.73B 7.09B 13.32B 911B 13.53B 91.76B 35.85B 448B 35.51B 34.75B 1,549B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-24 $129.31 -1.18% 5,529,581
26-07-23 $130.86 +0.40% 6,299,287
26-07-22 $130.34 +0.05% 4,757,764
26-07-21 $130.28 -2.20% 8,371,109
26-07-20 $133.21 -0.80% 4,103,979
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
129.31USD
Average target price
157.56USD
Spread / Average Target
+21.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock